154 related articles for article (PubMed ID: 12076307)
21. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
22. Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle.
Yoshida A; Fuchihata Y; Kuraoka S; Osano A; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
Urology; 2013 Apr; 81(4):920.e1-5. PubMed ID: 23497983
[TBL] [Abstract][Full Text] [Related]
23. 1-(2-pyrimidinyl)-piperazine, a buspirone metabolite, modulates bladder function in the anesthetized rat.
Myers RA; Plym MJ; Signor LJ; Lodge NJ
Neurourol Urodyn; 2004; 23(7):709-15. PubMed ID: 15382198
[TBL] [Abstract][Full Text] [Related]
24. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity.
Stahl MM; Ekström B; Sparf B; Mattiasson A; Andersson KE
Neurourol Urodyn; 1995; 14(6):647-55. PubMed ID: 8750383
[TBL] [Abstract][Full Text] [Related]
25. Tolterodine: an overview.
Wefer J; Truss MC; Jonas U
World J Urol; 2001 Nov; 19(5):312-8. PubMed ID: 11760779
[TBL] [Abstract][Full Text] [Related]
26. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
[TBL] [Abstract][Full Text] [Related]
27. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers.
Chapple CR; Nilvebrant L
Drugs R D; 2002; 3(2):75-81. PubMed ID: 12001821
[TBL] [Abstract][Full Text] [Related]
28. Tolterodine.
Hills CJ; Winter SA; Balfour JA
Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
[TBL] [Abstract][Full Text] [Related]
29. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Moro C; Uchiyama J; Chess-Williams R
Urology; 2011 Dec; 78(6):1442.e9-15. PubMed ID: 22001099
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterisation of the enantiomers of BM-5, a muscarinic partial agonist with opposed enantioselectivity between affinity and efficacy.
Sundquist S; Modiri AR; Nilsson BM; Hacksell U; Gillberg PG; Nilvebrant L
Pharmacol Toxicol; 2000 Jan; 86(1):44-50. PubMed ID: 10720106
[TBL] [Abstract][Full Text] [Related]
31. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R
BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132
[TBL] [Abstract][Full Text] [Related]
32. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
Sun F; Sui C; Zhou Y; Liu X; Shi Y; Wu Y; Li Y
Int J Pharm; 2013 Sep; 454(1):532-8. PubMed ID: 23891744
[TBL] [Abstract][Full Text] [Related]
33. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
34. Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction.
Fey TA; Gopalakrishnan M; Strake JG; King LL; Brioni JD; Sullivan JP; Coghlan MJ; Brune ME
Neurourol Urodyn; 2003; 22(2):147-55. PubMed ID: 12579633
[TBL] [Abstract][Full Text] [Related]
35. Muscarinic receptor binding of fesoterodine, 5-hydroxymethyl tolterodine, and tolterodine in rat tissues after the oral, intravenous, or intravesical administration.
Yamada S; Kuraoka S; Ito Y; Kato Y; Onoue S
J Pharmacol Sci; 2019 May; 140(1):73-78. PubMed ID: 31153768
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
[TBL] [Abstract][Full Text] [Related]
38. In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
Maruyama S; Hasuike N; Suzuki K; Yamada S
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):463-71. PubMed ID: 18074121
[TBL] [Abstract][Full Text] [Related]
39. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.
Kim Y; Yoshimura N; Masuda H; De Miguel F; Chancellor MB
BJU Int; 2006 Feb; 97(2):400-3. PubMed ID: 16430654
[TBL] [Abstract][Full Text] [Related]
40. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Brynne N; Böttiger Y; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
